nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.04.2004 | Review Article

Levamisole in Dermatology

A Review

verfasst von: Dr Noah Scheinfeld, Joshua D. Rosenberg, Jeffrey M. Weinberg

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Abstract

Levamisole, an anthelmintic agent with a wide range of immunomodulatory actions, has been used successfully as monotherapy and an adjunct to treatment in a variety of diseases. Since 1990, combination therapy of levamisole and fluorouracil has played an important role in the treatment of resected Dukes stage C adenocarcinoma of the colon. Because of its immunomodulating effects levamisole has been used in a wide range of diseases with and without success. In dermatologic disease levamisole has been successfully used in the treatment of parasitic, viral and bacterial infections including leprosy, collagen vascular diseases, inflammatory skin diseases and children with impaired immune a variety of reasons. It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth. Adverse affects of levamisole are mild and infrequent and include rash, nausea, abdominal cramps, taste alteration, alopecia, arthralgia, and a flu-like syndrome. It can rarely cause agranulocytosis. More studies need to be undertaken to study the full potential of levamisole in dermatologic diseases.

Assem ESK. Textbook of immunopharmacology. Dale MM, Foreman JC, editors. London: Blackwell Science Publications, 1984: 333–9

Gennaro AR. Remington: the science and practice of pharmacy. 19th ed. Easton (PA): Mack Publishing Co., 1995: 101–2

Hadden JW. T-cell adjuvants. Int J Immunopharmacol 1994; 16: 703–10PubMedCrossRef

Szeto C, Gillespie KM, Mathieson PW. Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology 2000; 100: 217–24PubMedCrossRef

Renoux G. The general immunopharmacology of levamisole. Drugs 1980; 19: 89–99CrossRef

Sun A, Chiang CP. Levamisole and/or Chinese medicinal herbs can modulate the serum level of squamous cell carcinoma associated antigen in patients with erosive oral lichen planus. J Oral Pathol Med 2001; 30: 542–8PubMedCrossRef

Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–8PubMedCrossRef

Alsaran K, Grisaru S, Stephens D, et al. Levamisole vs cyclophosphamide for frequently-relapsing steroid-dependent nephrotic syndrome. Clin Nephrol 2001; 56: 289–94PubMed

Renoux G. Modulation of immunity by levamisole. J Pharmacol Ther 1978; 2: 288–96

10.

Sweetman SC. Martindale: the complete drug reference. 33rd ed. Chicago (IL): Pharmaceutical Press, 2002: 1253–4

11.

Roberts G. Levamisole. IPCS INCHEM Canada [online]. Available from URL: http://www.inchem.org/documents/jecfa/jecmono/v33je02.htm [Accessed 2004 Mar 19]

12.

Symoens J, Veys E, Mielants M, et al. Adverse reactions to levamisole. Cancer Treat Rep 1978; 62: 1721–30PubMed

13.

Hook CC, Kimmel DW, Kvols LK, et al. Mutlifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992; 31: 262–7PubMedCrossRef

14.

Kimmel DW, Schutt AJ. Mutlifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy. Mayo Clin Proc 1993; 68: 363–5PubMedCrossRef

15.

Lucia P, Pocek M, Passacantando A, et al. Multifocal leukoencephalopathy induced by levamisole [letter]. Lancet 1996; 348: 1450PubMedCrossRef

16.

Secher L, Permin H, Skov PS, et al. Levamisole-induced hypersensitivity. Acta Derm Venereol 1978; 58: 372–4PubMed

17.

Kirby JD, Black M, McGibbon D. Levamisole-induced lichenoid eruptions. J R Soc Med 1980; 73: 208–11PubMed

18.

Clavere P, Bonnafoux-Clavere A, Delrous JL, et al. Fixed pigmented erythema caused by levamisole administration. Ann Dermatol Venereol 1994; 121: 238–9PubMed

19.

Fellner MJ, Ledesma GN. Leg ulcers secondary to drug reactions. Clin Dermatol 1990; 8: 144–9PubMedCrossRef

20.

Scheinberg MA, Bezerra JB, Almeida FA, et al. Cutaneous necrotising vasculitis induced by levamisole [letter]. BMJ 1978; 18: 408CrossRef

21.

Powell J, Grech H, Holder J. A boy with cutaneous necrosis occurring during treatment with levamisole. Clin Exp Dermatol 2002; 27: 32–3PubMedCrossRef

22.

Rongioletti F, Ghio L, Ginevri F, et al. Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long-term treatment with levamisole in children. Br J Dermatol 1999; 140: 948–51PubMedCrossRef

23.

Menni S, Pistritto G, Gianotti R, et al. Ear lobe bilateral necrosis by levamisole-induced occlusive vasculitis in a pediatric patient. Pediatr Dermatol 1997; 14: 477–9PubMedCrossRef

24.

Papageorgiou P, Kesarwala HH, Alcid DV, et al. Levamisole in chronic pyoderma. J Clin Lab Immunol 1982; 8: 121–7PubMed

25.

Djawari D, Hornstein OP. Recurrent chronic pyoderma with cellular immunodeficiency: successful therapy by levamisole. Dermatologica 1980; 161: 116–23PubMedCrossRef

26.

Svejgaard E, Christiansen AH, Stahl D, et al. Clinical and immunological studies in chronic dermatophytosis caused by Trichophyton rubrum. Acta Derm Venereol 1984; 64: 493–500PubMed

27.

Butler PG. Levamisole therapy of chronic Leishmania tropica. J Trop Med Hyg 1978; 81: 221–4PubMed

28.

Paul Y, Singh J. Cutaneous larva migrans in an infant. Indian Pediatr 1994; 31: 1089–91PubMed

29.

Namazi MR. Levamisole: a safe and economical weapon against pediculosis. Int J Dermatol 2001; 40: 292–4PubMedCrossRef

30.

Raptopoulou GM, Kountouras J, Goulis G. Levamisole in the treatment of chronic brucellosis. J Immunopharmacol 1980; 2: 85–97

31.

Haneke E. Levamisole therapy under different dermatological indications. Z Hautkr 1979; 54: 408–14PubMed

32.

Russell AS, Brisson E, Grace M. A double-blind controlled trial of levamisole in the treatment of recurrent herpes labialis. J Infect Dis 1978; 137: 597–600PubMedCrossRef

33.

Constantopoulos A, Lagos P, Benetos S, et al. Disseminated neonatal herpes simplex infection treated with levamisole: report of a case. Dermatologica 1980; 160: 121–4PubMedCrossRef

34.

Smirnov IuK, Shishov AS, Bagrov FI, et al. Levamisole in the treatment of different forms of herpes zoster. Zh Nevropatol Psikhiatr Im S S Korsakova 1983; 83: 511–5PubMed

35.

Parsad D, Pandhi R, Juneja A, et al. Cimetidine and levamisole versus cimetidine alone for recalcitrant warts in children. Pediatr Dermatol 2001; 18: 349–52PubMedCrossRef

36.

Parsad D, Saini R, Negi KS. Comparison of combination of cimetidine and levamisole with cimetidine alone in the treatment of recalcitrant warts. Australas J Dermatol 1999; 40: 93–5PubMedCrossRef

37.

Amer M, Tosson Z, Soliman A, et al. Verrucae treated by levamisole. Int J Dermatol 1991; 30: 738–40PubMedCrossRef

38.

Saul A, Sanz R, Gomez M. Treatment of multiple viral warts with levamisole. Int J Dermatol 1980; 19: 342–3PubMedCrossRef

39.

Schou M, Helin P. Levamisole in a double-blind study: no effect on warts. Acta Derm Venereol 1977; 57: 449–54PubMed

40.

Patrone F, Dallegri F, Bonvini E, et al. Disorders of neutrophil function in children with recurrent pyogenic infections. Med Microbiol Immunol (Berl) 1982; 171: 113–22CrossRef

41.

Businco L, Laurenti F, Rossi P, et al. A child with atopic features, raised serum IgE, and recurrent infection treated with levamisole. Arch Dis Child 1981; 56: 60–3PubMedCrossRef

42.

Verhaegen H, De Cree J, De Cock W, et al. Levamisole treatment of a child with severe aphthous stomatitis and neutropenia. Postgrad Med J 1976; 52: 511–4PubMedCrossRef

43.

Prakash MS, Rao VM, Reddy V. Effect of levamisole on the immune status of malnourished children. J Trop Pediatr 1998; 44: 165–6PubMedCrossRef

44.

Ellegaard J, Boesen AM. Restoration of defective cellular immunity by levamisole in a patient with immunoblastic lymphadenopathy: levamisole therapy for cellular immunologic deficiency with high IgE values. Scand J Haematol 1976; 17: 36–43PubMedCrossRef

45.

Sharma L, Thalliath GH, Girgia HS, et al. A comparative evaluation of levamisole in leprosy. Indian J Lepr 1985; 57: 11–6PubMed

46.

Bera DK, Sen PC. Effect of levamisole on bacterial index in BL and LL leprosy. Int J Lepr Other Mycobact Dis 1985; 53: 198–200PubMed

47.

Arora SK, Singh G, Sen PC. Immuno-stimulatory effect of levamisole in borderline leprosy cases. Indian J Lepr 1985; 57: 22–6PubMed

48.

Haneke E. Levamisole treatment of acne fulminans. Z Hautkr 1981; 56: 1160–6PubMed

49.

Lu SY, Chen WJ, Eng HL. Response to levamisole and low-dose prednisolone in 41 patients with chronic oral ulcers: a 3-year open clinical trial and follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 86: 438–45PubMedCrossRef

50.

Lozada F, Silverman S, Cram D. Pemphigus vulgaris: a study of six cases treated with levamisole and prednisone. Oral Surg Oral Med Oral Pathol 1982; 54: 161–5PubMedCrossRef

51.

Mashkilleson NA. Exacerbation of the course of pemphigus vulgaris after taking levamisole. Vestn Dermatol Venerol 1980; Oct (10): 46–8

52.

Brzezinska-Wcislo L, Krauze E, Suwala-Jurczyk B. Levamisole in the treatment of crural ulcers. Przegl Dermatol 1990; 77: 51–5PubMed

53.

Jautova J, Jarcuskova D, Dubivska M, et al. Immunostimulation therapy in patients with alopecia areata. Bratisl Lek Listy 1995; 96: 160–4PubMed

54.

de Metieux P, Spitler LE, Paulus HE. Treatment of Behcet syndrome with levamisole. Arthritis Rheum 1981; 24: 64–70CrossRef

55.

Pachor ML, Bambara LM, Lunardi C, et al. Behcet’s syndrome: description of a clinical case. Minerva Med 1982; 73: 3411–6PubMed

56.

Lozada-Nur F, Cram D, Gorsky M. Clinical response to levamisole in thirty-nine patients with erythema multiforme: an open prospective study. Oral Surg Oral Med Oral Pathol 1992; 74: 294–8PubMedCrossRef

57.

Lozada-Nur F, Gorsky M, Silverman Jr S. Oral erythema multiforme: clinical observations and treatment of 95 patients. Oral Surg Oral Med Oral Pathol 1989; 67: 36–40PubMedCrossRef

58.

Lozada F. Levamisole in the treatment of erythema multiforme: a double-blind trial in fourteen patients. Oral Surg Oral Med Oral Pathol 1982; 53: 28–31PubMedCrossRef

59.

Scherak O, Smolen J, Kolarz G, et al. Clinical experience with levamisole treatment of patients with systemic lupus erythematosus. Wien Klin Wochenschr 1979; 91: 758–62PubMed

60.

Tay C. Eosinophilic arthritis. Rheumatology (Oxford) 1999; 38: 1188–94CrossRef

61.

Runge LA, Pinals RS, Tomar RH. Treatment of rheumatoid arthritis with levamisole: long-term results and immune changes. Ann Rheum Dis 1979; 38: 122–7PubMedCrossRef

62.

Rondier J, Cayla J, Tron F, et al. Controlled trial of levamisole in rheumatoid arthritis: clinical and immunological study of 22 cases. Nouv Presse Med 1978; 7: 3023–7, 3029–30PubMed

63.

Basch CM, Spitler LE, Engleman EG, et al. Cellular immune reactivity in patients with rheumatoid arthritis and effects of levamisole. J Rheumatol 1977; 4: 377–88PubMed

64.

Huskisson EC, Scott J, Balme HW, et al. Immunostimulant therapy with levamisole for rheumatoid arthritis. Lancet 1976; I: 393–5CrossRef

65.

Veys EM, Mielants H, Verbruggen G. Goldsalts, levamisole and D-penicillamine as first choice slow-acting antirheumatic drugs in rheumatoid arthritis: a long-term follow-up study. Clin Exp Rheumatol 1987; 5: 111–6PubMed

66.

Lu SY, Chen WJ, Eng HL. Dramatic response to levamisole and low-dose prednisolone in 23 patients with oral lichen planus: a 6-year prospective follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 80: 705–9PubMedCrossRef

67.

Pasricha JS, Khera V. Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease. Int J Dermatol 1994; 33: 584–7PubMedCrossRef

68.

Sanchez MR. Miscellaneous treatments: thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine. Clin Dermatol 2000; 18: 131–45PubMedCrossRef

69.

Medvedev IuA, Alekhin EK, Leshchenko VM. Use of immunostimulants in the treatment of a zooanthroponotic trichophyton infection. Vestn Dermatol Venerol 1987; 11: 70–3PubMed

70.

Butler PG. Levamisole and immune response phenomena in cutaneous leishmaniasis. J Am Acad Dermatol 1982; 6: 1070–7PubMedCrossRef

71.

Makled M, Rifaat M, Azab M, et al. Determination of healing response by immunostimulant therapy (levamisole) in cutaneous leishmaniasis. Chemioterapia 1987; 6 (2 Suppl.): 214–6PubMed

72.

Chong H. Oriental sore: a look at trends in and approaches to the treatment of leishmaniasis. Int J Dermatol 1986; 25: 615–23PubMedCrossRef

73.

Mukovozova LA. Effect of levamisole on the cellular and humoral immunity indices in patients with chronic brucellosis. Zh Mikrobiol Epidemiol Immunobiol 1988; 10: 45–9PubMed

74.

Mukovozova LA. Effect of levamisole on the cellular immunity indices of patients with active forms of brucellosis. Zh Mikrobiol Epidemiol Immunobiol 1988; 6: 61–5PubMed

75.

Thornes RD. Chronic human brucellosis and anti-anergic treatment with levamisole. Vet Rec 1977; 101: 27–30PubMedCrossRef

76.

Katzung BG. Basic and clinical pharmacology. 8th ed. Norwalk (CT): Lange Medical Books/McGraw Hill, 2001

77.

National Center for Infectious Diseases. Infectious disease index [online]. Available from URL: http://www.cdc.gov/ncidod/index.htm [Accessed 2003 Mar 26]

78.

Dale MM, Foreman JC, editors. Textbook of immunopharmacology. London: Blackwell Scientific Publications, 1984: 333–9

79.

Seidlin M, Straus SE. Treatment of mucocutaneous herpes simplex infection. Clin Dermatol 1984; 2: 100–16PubMedCrossRef

80.

Donabedian H, Gallin JI. The hyperimmunoglobulin E recurrent-infection (Job’s) syndrome: a review of the NIH experience and the literature. Medicine 1983; 62: 195–208

81.

Vanheule R, De Cree J, Adriaenssens K, et al. Levamisole therapy for cellular immunologic deficiency with high IgE values. Acta Paediatr Belg 1976; 29: 41–6PubMed

82.

McManus AT. Examination of neutrophil function in a rat model of decreased host resistance following burn trauma. Rev Infect Dis 1983; 5 Suppl. 5: S898–907CrossRef

83.

Stinnett JD, Loose LD, Miskell P, et al. Synthetic immunomodulators for prevention of fatal infections in burned guinea pig model. Ann Surg 1983; 198: 53–7PubMedCrossRef

84.

Matachin EN, Atiasov NI, Zuev PD, et al. Methods of correction of humoral and cellular immunity in patients with burns and erosive-ulcerative lesions of the gastrointestinal tract. Vestn Khir Im I I Grek 1990; 144: 44–9

85.

Katoch K. Immunotherapy of leprosy. Indian J Lepr 1996; 68: 349–61PubMed

86.

Martinez D, Zaias N. Levamisole as adjunct to dapsone in leprosy. Lancet 1976; II: 209–10CrossRef

87.

Carli-Basset C, Renoux M, Pauley AM, et al. Correlation between the immune reaction and clinical course in a bullous pemphigoid case treated with levamisole. LARC Med 1982; 2 (5): 400–41

88.

Liapon AO, Rutshtein LG, Roitburd MF, et al. Levamisole (decaris) in the complex treatment of different clinical forms of psoriasis. Vestn Dermatol Venerol 1984; 4: 61–6PubMed

89.

Sehgal VN, Jain S, Kumar S, et al. Generalized lichen nitidus in a child’s response to cetirizine dihydrochloride/levamisol [letter]. Australas J Dermatol 1998; 39: 60PubMed

90.

Boyd AS. New and emerging therapies for lichenoid dermatoses. Dermatol Clin 2000; 18: 21–9PubMedCrossRef

91.

Lavery HA, Pinkerton JH. Successful treatment of Behcet’s syndrome with levamisole. Br J Dermatol 1985; 113: 372–3PubMedCrossRef

92.

Bang D. Treatment of Behcet’s disease. Yonsei Med J 1997; 38: 401–10PubMed

93.

Borrego LC, Escobar AS, Averhoff Casamayor MC, et al. Behcet’s syndrome: report of the first case in Cuba. Rev Cubana Estomatol 1989; 26: 175–80PubMed

94.

Wechsler B, Le Thi Huong DU, Godeau P. Medical treatment of Behcet’s disease. J Mal Vasc 1988; 13: 262–9PubMed

95.

Dhar S, Kanwar AJ, Ghosh S. Levamisole in erythema multiforme. Oral Surg Oral Med Oral Pathol 1993; 76: 678–9PubMedCrossRef

96.

Ogawa K, Sano T, Hisano G, et al. Levamisole in systemic lupus erythematosus. Ann Allergy 1979; 43: 187–9PubMed

97.

Smolen J, Scherak O, Menzel J, et al. Levamisole in systemic lupus erythematosus. Arthritis Rheum 1977; 20: 1558–9PubMedCrossRef

98.

Karchova TIu, Demin AA. The present-day treatment of systemic lupus erythematosus. Revmatologiia (Mosk) 1989; 4: 59–66

99.

Veys EM, Mielants H, Verbruggen G, et al. Levamisole as basic treatment of rheumatoid arthritis: long-term evaluation. J Rheumatol 1981; 8: 45–6PubMed

100.

Mowat AG. Levamisole and cellular immunity in rheumatoid arthritis: a review. J Rheumatol Suppl 1978; 4: 55–61PubMed

101.

Yunus MB. Investigational therapy in rheumatoid arthritis: a critical review. Semin Arthritis Rheum 1988; 17: 163–84PubMedCrossRef

102.

Balabanova RM, Barakat B. Immunomodulating therapy of rheumatoid arthritis. Revmatologiia (Mosk) 1990; 3: 38–44

103.

Hernandez-Perez E. Levamisole plus indomethacin in the treatment of herpes simplex. Dermatologica 1980; 160 (2): 118–20PubMedCrossRef

104.

Tanphaichitra D, Srimuang S. Efficacy of acyclovir combined with immunopotentiating agents in the treatment of varicella-zoster. J Antimicrob Chemother 1987; 19: 255–62PubMedCrossRef

105.

Glick M, Muzyka BC. Alternative therapies for major aphthous ulcers in AIDS patients. J Am Dent Assoc 1992; 123: 61–5PubMed

106.

Wiggington JM. Reversal of ferritin mediated immunosuppression by levamisole: a rationale for its application to the management of the acquired immune deficiency syndrome (AIDS). Med Hypotheses 1995; 44: 85–8CrossRef

107.

Bourinbaiar AS, Lee-Huang S, Krasinski K, et al. Anti-HIV effect of immunomodulating agent, levamisole, in vitro. Biomed Pharmacother 1994; 48: 327–30PubMedCrossRef

108.

White CR, Hanifin JM. Levamisole therapy in atopic dermatitis: Randomized double-blind evaluation. Arch Dermatol 1978; 114: 1314–5PubMedCrossRef

109.

Sachar DB, Rubin KP, Gumaste V. Levamisole in Crohn’s disease: a randomized, double-blind, placebo-controlled clinical trial. Am J Gastroenterol 1987; 82: 536–9PubMed

110.

Dickler MN, Coit DG, Meyers ML. Adjuvant therapy of malignant melanoma. Surg Oncol Clin N Am 1997; 6: 793–812PubMed

111.

Sondak VK, Wolfe JA. Adjuvant therapy for melanoma. Curr Opin Oncol 1997; 9: 189–204PubMedCrossRef

112.

Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991; 9: 736–40PubMed

113.

Loutfi A, Shakr A, Jerry M, et al. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 1987; 10: 325–8PubMed

114.

Quirt IC, Shelley WE, Pater JL, et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1991; 9: 729–35PubMed

115.

Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995; 75 (2 Suppl.): 726–34PubMedCrossRef

116.

Wanebo HJ, Hilal EY, Pinsky CM, et al. Randomized trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report. Cancer Treat Rep 1978; 62: 1663–9PubMed

117.

Olivari AJ, Glait HM, Guardo A, et al. Levamisole in squamous cell carcinoma of the head and neck. Cancer Treat Rep 1979; 63: 983–90PubMed

118.

Hazen PG, Kallor A, Michel B. Effects of levamisole in Sezary syndrome: apparent acceleration of disease. Dermatologica 1979; 159: 461–5PubMedCrossRef

119.

Arora SK, Singh G, Sen PC. Levamisole in cases of ENL. Indian J Lepr 1985; 57: 17–21PubMed

120.

Singh NK, Jha TK, Singh IJ, et al. Combination therapy in Kala-azar. J Assoc Physicians India 1995; 43: 319–20PubMed

121.

Veien NK. Cutaneous sarcoidosis: prognosis and treatment. Clin Dermatol 1986; 4: 75–87PubMedCrossRef

122.

Veien NK. Cutaneous sarcoidosis treated with levamisole. Dermatologica 1977; 154: 185–9PubMedCrossRef

123.

Cole PJ, Citron KM, Plowman PN, et al. The treatment of sarcoidosis by levamisole. Br J Dis Chest 1979; 73: 367–72PubMedCrossRef

124.

Folkers E, Tafelkruyer J. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease): therapeutic problems. Br J Dermatol 1978; 98: 681–4PubMedCrossRef

Titel: Levamisole in Dermatology
A Review
verfasst von: Dr Noah Scheinfeld
Joshua D. Rosenberg
Jeffrey M. Weinberg
Publikationsdatum: 01.04.2004
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 2/2004
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.2165/00128071-200405020-00004

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Levamisole in Dermatology

A Review

Abstract

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2004

Fixed-Dose Combination Therapy for Psoriasis

Topical Methyl Aminolevulinate

Topical Antibacterial Treatments for Acne Vulgaris

Topical Methyl Aminolevulinate

Prurigo

Topical Methyl Aminolevulinate

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie